Repligen Corporation $RGEN Shares Purchased by Allspring Global Investments Holdings LLC

Allspring Global Investments Holdings LLC boosted its stake in Repligen Corporation (NASDAQ:RGEN) by 2.4% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 311,175 shares of the biotechnology company’s stock after buying an additional 7,430 shares during the quarter. Allspring Global Investments Holdings LLC’s holdings in Repligen were worth $51,142,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of RGEN. United Capital Financial Advisors LLC purchased a new stake in Repligen during the 3rd quarter worth approximately $368,387,000. Holocene Advisors LP lifted its position in shares of Repligen by 47.0% in the third quarter. Holocene Advisors LP now owns 1,377,104 shares of the biotechnology company’s stock valued at $184,077,000 after acquiring an additional 440,290 shares in the last quarter. Alliancebernstein L.P. lifted its position in shares of Repligen by 21.8% in the third quarter. Alliancebernstein L.P. now owns 1,104,171 shares of the biotechnology company’s stock valued at $147,595,000 after acquiring an additional 197,778 shares in the last quarter. Brown Capital Management LLC boosted its stake in shares of Repligen by 16.3% in the second quarter. Brown Capital Management LLC now owns 1,005,276 shares of the biotechnology company’s stock worth $125,036,000 after acquiring an additional 141,241 shares during the last quarter. Finally, Dimensional Fund Advisors LP boosted its stake in shares of Repligen by 4.1% in the third quarter. Dimensional Fund Advisors LP now owns 799,510 shares of the biotechnology company’s stock worth $106,826,000 after acquiring an additional 31,505 shares during the last quarter. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

RGEN has been the subject of several recent research reports. UBS Group reduced their price objective on Repligen from $200.00 to $195.00 and set a “buy” rating for the company in a research note on Wednesday, February 25th. Weiss Ratings cut shares of Repligen from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Tuesday, March 3rd. Barclays dropped their target price on shares of Repligen from $200.00 to $175.00 and set an “overweight” rating for the company in a report on Wednesday, February 25th. HC Wainwright raised their price target on shares of Repligen from $180.00 to $208.00 and gave the stock a “buy” rating in a research note on Monday, March 23rd. Finally, Wells Fargo & Company decreased their price target on shares of Repligen from $190.00 to $180.00 and set an “overweight” rating on the stock in a research note on Wednesday, February 25th. One research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $176.92.

Repligen Stock Up 0.4%

NASDAQ RGEN opened at $118.32 on Thursday. The business’s fifty day simple moving average is $132.26 and its 200-day simple moving average is $146.45. The company has a quick ratio of 7.12, a current ratio of 8.37 and a debt-to-equity ratio of 0.26. The firm has a market cap of $6.66 billion, a PE ratio of 139.20, a P/E/G ratio of 2.30 and a beta of 1.19. Repligen Corporation has a 52 week low of $102.96 and a 52 week high of $175.77.

Repligen (NASDAQ:RGEN) last announced its quarterly earnings data on Tuesday, February 24th. The biotechnology company reported $0.49 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.44 by $0.05. Repligen had a net margin of 6.62% and a return on equity of 4.71%. The firm had revenue of $197.91 million during the quarter, compared to analyst estimates of $192.23 million. During the same quarter in the prior year, the firm posted $0.44 earnings per share. Repligen’s quarterly revenue was up 18.1% on a year-over-year basis. Repligen has set its FY 2026 guidance at 1.930-2.010 EPS. As a group, equities analysts anticipate that Repligen Corporation will post 1.72 earnings per share for the current year.

Repligen Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.